

Angela Cioffi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1576558/publications.pdf>

Version: 2024-02-01

27
papers

2,101
citations

331670

21
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

2795
citing authors

#	ARTICLE	IF	CITATIONS
1	Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 942-949.	10.7	260
2	Malignant Peripheral Nerve Sheath Tumors. <i>Oncologist</i> , 2014, 19, 193-201.	3.7	258
3	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. <i>Lancet Oncology</i> , The, 2011, 12, 1045-1052.	10.7	212
4	Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). <i>Oncologist</i> , 2012, 17, 1213-1220.	3.7	182
5	Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. <i>International Journal of Cancer</i> , 2006, 119, 706-711.	5.1	169
6	Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). <i>European Journal of Cancer</i> , 2010, 46, 1344-1351.	2.8	118
7	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012, 118, 3330-3336.	4.1	118
8	Sorafenib in patients with progressive epithelioid hemangioendothelioma. <i>Cancer</i> , 2013, 119, 2639-2644.	4.1	97
9	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015, 51, 210-217.	2.8	97
10	Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2011, 47, 515-519.	2.8	72
11	Age-Stratified Risk of Unexpected Uterine Sarcoma Following Surgery for Presumed Benign Leiomyoma. <i>Oncologist</i> , 2015, 20, 433-439.	3.7	59
12	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. <i>Annals of Surgical Oncology</i> , 2012, 19, 1551-1559.	1.5	57
13	Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. <i>Investigational New Drugs</i> , 2012, 30, 765-771.	2.6	57
14	Treating soft tissue sarcomas with adjuvant chemotherapy. <i>Current Treatment Options in Oncology</i> , 2011, 12, 21-31.	3.0	53
15	Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. <i>Targeted Oncology</i> , 2013, 8, 211-213.	3.6	47
16	Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics. <i>Clinical Cancer Research</i> , 2013, 19, 1190-1196.	7.0	46
17	GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1849-1854.	1.6	41
18	Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 357-367.	2.3	32

#	ARTICLE	IF	CITATIONS
19	Angiosarcomas and Other Sarcomas of Endothelial Origin. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 975-988.	2.2	32
20	Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). <i>Cancer</i> , 2018, 124, 1449-1454.	4.1	32
21	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015, 51, 852-860.	2.8	23
22	Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumor. <i>European Journal of Endocrinology</i> , 2012, 166, 131-135.	3.7	19
23	Consumptive Coagulopathy in Angiosarcoma: A Recurrent Phenomenon?. <i>Sarcoma</i> , 2014, 2014, 1-7.	1.3	13
24	Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 113-122.	3.3	4
25	A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8579-8579.	1.6	3
26	Stratégie de prise en charge des tumeurs primitives. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2008, 75, 362-368.	0.0	0
27	The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 653-664.	0.8	0